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Endometrial carcinoma is the commonest type of female genital tract malignancy in the developed countries. Endometrial carcin-
oma is usually conﬁned to the uterus at the time of diagnosis and as such usually carries an excellent prognosis with high curabili-
ty. Our understanding and management of endometrial cancer have continuously developed. Current controversies focus on
screening and early detection, the extent of nodal surgery, and the changing roles of radiation therapy and chemotherapy and will
be discussed in this paper.
1.Introduction
Endometrial carcinoma is the commonest type of female
genitaltractmalignancyinthedevelopedcountries,account-
ing for nearly 50% of all new gynecologic cancers diagnosed
in the Western world. Worldwide, endometrial cancer is only
second to cervical cancer in frequency [1]. Most cases (75–
85%) of endometrial carcinoma occur in the sixth and sev-
enth decades of life, and 95% occur in patients over 40 years
of age [2, 3].
Endometrial carcinoma is usually conﬁned to the uterus
at the time of diagnosis and as such usually carries an excel-
lent prognosis with high curability [4, 5]. However, patients
with high-risk factors including increased age, higher tumor
grade, aggressive histology, and advanced stage represent real
challenges.
Ourunderstandingandmanagementofendometrialcan-
cer have continuously developed. The surgical approach has
expanded to include pelvic and para-aortic lymphadenec-
tomy, although debatable, and acceptance of laparoscopic
management. There have been important developments in
chemotherapy in endometrial cancer, which may be promis-
ing in an adjuvant setting [6]. Hormonal therapy remains an
important option and our understanding of the biology of
the disease may help determine which patients may beneﬁt
most [7]. Current controversies focus on screening and early
detection, the extent of nodal surgery, and the changing roles
of radiation therapy and chemotherapy and will be discussed
in this paper.
2. Screening
Many endometrial cancers develop by way of a precursor
lesion. Estrogen-related cancers frequently develop second-
ary to atypical endometrial hyperplasia (AEH) or demon-
strate AEH in the uterus at the time of hysterectomy. Ser-
ous tumors also may develop through a precursor lesion,
endometrial intraepithelial carcinoma (EIC) [8, 9]. Prompt
identiﬁcation of precursor lesions might potentially provide
an opportunity to prevent cancers. However, mass screening
of the population for endometrial cancer is not practical due
to the low prevalence of the disease and as the ideal method
for endometrial surveillance is yet to be devised [10, 11].
There is no blood test of suﬃcient sensitivity and speciﬁcity,
and routine mass screening with pelvic ultrasound scans or
endometrial biopsies is not practical.
Malignant endometrial cells appear on Papanicolaou
(Pap) smear in 25–50% of women with endometrial cancer
[12–14]. However, this group is more likely to have deeper
myometrialinvasion,highertumorgrade,positiveperitoneal
cytologic ﬁndings, and a more advanced stage of disease at2 Obstetrics and Gynecology International
presentation [15]. The signiﬁcance of normal endometrial
cells in cervical smears in postmenopausal women is less
clear. In asymptomatic postmenopausal women, the preva-
lencerateof(pre-)malignantuterinediseasewassigniﬁcantly
higher (6.5%) as compared to smears without these normal
endometrial cells (0.2%) [16].
As there is no eﬀective screening, management requires
the prompt assessment of symptomatic patients, especially
those at high risk. It is appropriate to evaluate individuals
past their fourth decade of life if there is abnormal bleed-
ing (i.e., intermenstrual bleeding, persistent blood stained
discharge, postcoital bleeding). Similarly, a higher degree of
suspicion should be held for younger patients with high-risk
characteristics including signiﬁcant obesity, polycystic ovar-
ian syndrome/chronic anovulation, or tamoxifen exposure.
A meta-analysis reported that the Pipelle was the
best endometrial sampling device, with detection rates for
endometrial cancer in postmenopausal and premenopausal
women of 99.6% and 91%, respectively. The sensitivity for
the detection of endometrial hyperplasia was 81%. The
speciﬁcity for all devices was 98% [17].
Screening and prevention strategies for women on tam-
oxifen are more challenging. Women with intact uteri who
take tamoxifen for either treatment or prevention of breast
cancer are at an increased risk of developing endometrial
cancer. However, this risk is outweighed by the reduction in
recurrenceorindevelopmentofacontralateralbreastcancer.
Women on tamoxifen should be advised to report abnormal
bleeding or vaginal discharge. Screening of asymptomatic
women on tamoxifen therapy with ultrasound or endome-
trial biopsies is not currently recommended [18, 19]. This
might become less of an issue over the next few years with
a move to the use of aromatase inhibitors as a substitute for
tamoxifen in the adjuvant treatment setting.
Oﬀering screening for the group of patients with clear
hereditary predisposition is equally challenging. Although
most cases of endometrial carcinoma are thought to be
sporadic, some cases clearly have a hereditary basis, the pro-
totype being the Lynch syndrome (hereditary nonpolypo-
sis colorectal cancer (HNPCC)). This is an autosomal-domi-
nant cancer susceptibility syndrome associated with early-
onset colon, rectal, ovary, small bowel, ureter/renal pelvis
cancers, and endometrial cancer. The lifetime risk of endo-
metrial cancer in Lynch syndrome women is 40% to 60%,
a risk similar to that of developing colon cancer [20]. It is
estimatedthat2–5%ofallendometrialcarcinomas,and10%
of endometrial cancers in women younger than 50 years, are
Lynch syndrome related [21].
Lynch syndrome results of a germ-cell line mutation in
one of the DNA mismatch repair genes (MSH2, MLH1, or
MSH6) [22]. Risk-reducing surgery (prophylactic hysterec-
tomy and bilateral salpingo-oophorectomy) has been shown
to be an eﬀective strategy for preventing ovarian and endo-
metrialandovariancancersinthesewomen[23].Thereisno
uniform screening strategy for these women. Currently, the
American Cancer Society recommends annual endometrial
biopsies starting at age 35 for women known to have or be
at risk for HNPCC and does not recommend ultrasound
scans. However, the National Comprehensive Cancer Center
(NCCC) guidelines state that annual endometrial biopsies
may only be useful in select patients. The NCCC guidelines
also state that transvaginal ultrasound for ovarian and
endometrial cancer detection may be considered at the
clinician’s discretion.
The relationship between BRCA1andBRCA2genes mut-
ations and the risk of endometrial cancer is controversial
and less clear than the role of BRCA1 and BRCA2 in heredi-
tary breast and ovarian/primary peritoneal cancers. Such an
association has been suggested [24] ,a n ds o m es t u d i e sh a v e
attempted to address this hypothesis but failed to demon-
strateanyincreaseinriskassociatedwithBRCA1andBRCA2
mutations compared to the general population [25, 26]. In
one study of 199Ashkenazi Jewish patients with endometrial
cancer, the frequency of germ-cell line BRCA1 and BRCA2
mutations (3 per 199, 1.5%) in endometrial cancer patients
was comparable to the baseline rate of 2% in the Ashkenazi
population, suggesting no increased risk [25]. In another
study, 857 known BRCA1 and BRCA2 carriers aged 45 to 70
were followed over time for the development of endometrial
cancer [26]. With an average length of followup of 3.3 years,
six women developed endometrial cancer. Four of the six
patients had used tamoxifen. Compared to the expected rate
ofendometrialcancerinageneralpopulation,BRCAcarriers
who did not receive tamoxifen did not have a signiﬁcant
increase in risk of developing endometrial cancer. Thus it
seems that screening for endometrial cancer is not warranted
in known BRCA1 or BRCA2 mutations carriers.
3.DeterminingtheSurgicalProcedure
The standard treatment for endometrial carcinoma remains
surgical and includes an initial exploration with collection
of peritoneal ﬂuid for cytologic evaluation (intraperitoneal
cell washings), total extrafascial hysterectomy with bilateral
salpingo-oophorectomy, and appropriate surgical staging in
patients considered at risk for extrauterine disease.
4. The Role of LaparscopicHysterectomy
Current evidence on the safety and eﬃcacy of laparoscopic
hysterectomy (including laparoscopic total hysterectomy and
laparoscopically assisted vaginal hysterectomy) for endome-
trial cancer is adequate to recommend the use of this
procedure. Patient selection for laparoscopic hysterectomy
for endometrial cancer should be carried out by a multidis-
ciplinary gynaecological oncology team, and advanced lapa-
roscopic skills are required for this procedure.
In a meta-analysis of 3 randomised controlled trials
(RCTs) including 359 patients with 38, 44, and 79 months of
followup,respectively,therewerenosigniﬁcantdiﬀerencesin
survival between laparoscopic hysterectomy (LH) and abdo-
minal hysterectomy (AH) [27, 28]. The overall survival rate
was 92% (169/184) for patients in the LH group and 88%
(154/175) for patients in the AH group (P = 0.976). The
disease-freesurvivalratewas88%(161/184) forLHand88%
(154/175) for AH (P = 0.986). A nonrandomised compara-
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rates of 98% for both LH and AH. The 5-year progression-
free survival rate was 96% for patients after LH and 97% for
patients after AH (P = 0.74) [29].
Similarratesofrecurrencewerenotedforpatientstreated
with LH or AH. Rates of recurrence after LH ranged between
9–20% compared to 12–18% after AH [30–32]. In one study,
including 40 patients treated by LH, there was a single case
of port-site recurrence (2.5%) after a median followup of
79 months [32]. The hospital stay after LH is statistically
signiﬁcantly shorter than after AH [30, 31], with the propor-
tion of patients staying more than 2 days being signiﬁcantly
higher in the AH group [33]. Conversion from laparoscopy
to laparotomy ranges from 0–26% with an average of 5–8%
[30, 31, 33–36]. Similar rates of intraoperative complications
have been reported for LH and AH, but signiﬁcantly fewer
postoperative complications for LH compared with AH [27,
28, 33].
The Laparoscopic Approach to Cancer of the Endometri-
um (LACE) trial is currently recruiting patients in Australia.
The primary objective of this study is to assess disease-free
survivalat4.5yearspostoperativelyforwomenwithapparent
stage I endometrial cancer, comparing patients who are ran-
domised to receive total laparoscopic hysterectomy (TLH)
and patients who are randomised to receive total abdom-
inal hysterectomy (TAH). The estimated enrolment is 640
patientsandthestudyisduetobecompletedin2014.Several
studies describe laparoscopic hysterectomy with robotic as-
sistance.
5. Peritoneal Cytology Results
After omission from the 2009 FIGO staging for endometrial
carcinoma, the need for and the signiﬁcance of a positive
peritoneal cytology result became controversial. However,
positive washings are most common in patients with grade 3
histologic types, metastases to the adnexae, deep myometrial
invasion, or positive pelvic or para-aortic nodes [37–43].
In a Gynaecologic Oncology Group (GOG) study of 697
patients with endometrial cancer, and with information on
peritoneal cytologic results and adequate followup, disease
recurred in 25 of 86 patients (29.1%) with positive washings,
compared with 64 of 611 patients (10.5%) with negative
washings [44]. In 17 of the 25 recurrences with positive
washings, the recurrences were outside the peritoneal cavity.
The relative risk of death for patients with positive cytologic
washings was increased threefold [45].
Positiveperitonealcytologywasreportedin8.3%,12.1%,
and 15.9% of stage I endometrial carcinoma patients with
grades 1, 2, and 3 histologic types, respectively [46]. Super-
ﬁcial and deep myometrial invasion were associated with
positive washings in 7.6% and 17.2% of the cases, respec-
tively [46]. It might be concluded that the poor prognosis
associated with malignant washings is a reﬂection of other
adverse prognostic factors.
Positiveperitonealcytologymaycarryaprognosticsigni-
ﬁcance only when the endometrial carcinoma has spread
beyond the uterus [47–50]. In patients with clinical stage I
and II endometrial carcinoma, positive peritoneal cytologic
results did not inﬂuence survival when the disease was con-
ﬁned to the uterus [43]. However, when the disease had
spread to the adnexa, lymph nodes, or peritoneum, then
positive peritoneal cytologic ﬁndings decreased the survival
rate from 73% to 13% at 5 years, but all recurrences were at
distantsites[43].Otherstudieshavefoundthatpositivecyto-
logy was an independent poor prognostic factor for patients
with stages I to IIIA disease [51, 52].
It could thus be concluded that the presence of positive
peritoneal washings is not an independent negative prog-
nostic indicator but potentiates other adverse prognostic
indicators [42].
6. SurgicalStaging andLymphadenectomy
In addition, many women will require some type of adjuvant
radiation therapy to help prevent vaginal vault recurrence
and to sterilize disease in lymph nodes. With the increasing
emphasis on surgico-pathologic staging, a more individual-
ized approach to adjuvant radiation is possible. However, the
need for pelvic and para-aortic lymphadenectomy remains a
topic of heated debate.
There is a lack of consensus on the extent of surgical
staging in endometrial carcinoma. The ability of surgical
staging to accurately identify lymphatic spread and how this
information aﬀects prognosis and alters the use of adjuvant
therapies are a source of controversy. When full surgical stag-
ing is performed, a bilateral pelvic and para-aortic lympha-
denectomy is increasingly advocated on all endometrial car-
cinoma patients because positive lymph nodes (including
isolated para-aortic lymph nodes) are common in all grades
[53]. In the GOG 33 study, 22% of patients with clinical
stageI and occult stageII endometrial carcinoma werefound
to have extrauterine spread at the time of surgery, with pelvic
and/or para-aortic metastases in 11% of women [37]. Other
studies have assessed various intraoperative parameters to
identify patients having an extremely low probability of lym-
phaticspreadinordertominimizeunder-andovertreatment
[54, 55].
It is suggested that lymphadenectomy improves the car-
cinoma-related survival and the recurrence-free survival in
high-risk endometrioid adenocarcinoma patients [56]. Con-
versely, lymphadenectomy does not appear to beneﬁt pa-
tients with grade 1 and 2 endometrioid lesions with myome-
trial invasion <50% and primary tumor diameter <2cm[53,
57]. It thus seems that there is increasing evidence against
the need to perform systematic lymphadenectomy in low-
risk cases (grade 1 or 2 endometrioid tumors conﬁned to the
inner half of the myometrium) [53].
Thedebateexistsﬁrstfortheneedforlymphadenectomy,
its extent, and whether it incurs a therapeutic beneﬁt.
6.1. No Lymphadenectomy. The majority of patients with
endometrial carcinoma are at low risk for nodal disease at
presentation, and treatment decisions can be based on ﬁnal
pathologic information. Thus if node dissection was to be
performed, the majority of patients would be node negative
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Radiation Therapy in Endometrial Cancer (PORTEC) trial
evaluated patients with stage IC, grade 1; stage IB-C, grade 2;
or stage IB, grade 3 (old FIGO staging system) who under-
went hysterectomy without lymph node dissection and com-
pared observation to postoperative pelvic radiation [58].
Favourable outcomes were observed both with and without
radiation therapy (5-year survival rates of 85% observation,
81% with pelvic radiation) [58].
Analysis of women with stage I endometrial cancer in the
US National Cancer Institute’s Surveillance Epidemiology
andEndResults(SEER)database(1988to1993)showedthat
5-year relative survival for patients without nodal dissection
was98%comparedto96%inthoseundergoingnodaldissec-
tion, thus suggesting no discernible beneﬁt for nodal dissec-
tion [55]. It could be argued that the increased use of radia-
tion in unstaged patients may produce similar outcomes to
patients who are staged and who avoid radiation therapy.
This was addressed by the randomized trial “A Study in the
Treatment of Endometrial Cancer” (ASTEC) that random-
ized patients with endometrial cancer treated with hysterec-
tomy to pelvic lymphadenectomy or not. Following surgery,
patients with stage I-IIA disease were then randomized again
to observation or pelvic radiation therapy if they had grade
3, serous, or clear cell histology; >50% myometrial invasion;
or endocervical glandular invasion (stage IIA). The results
suggested that there was no advantage for routine lympha-
denectomy [57].
However, without the node dissection information, the
surgeon must rely on uterine factors to estimate the prob-
ability for nodal disease and pelvic failure to determine the
needforpostoperativeradiation,whichcouldresultinasub-
stantial increase in the use of radiation and overtreatment of
patients. Interestingly, omitting nodal dissection may also
lead to poorer prognosis. For instance, a subset of 99 patients
with stage IC, grade 3 endometrial cancer, who did not have
lymph node dissection, were treated with pelvic radiation
and followed prospectively within the PORTEC trial [59].
Five-year survival for this group of patients was 58%, and
12% had vaginal or pelvic failures despite whole pelvic radia-
tion, which is poorer than what has been reported in pa-
tients with stage IIIC endometrial cancer managed by lym-
phadenectomy followed by radiation [60–62].
6.2. Selective Nodal Dissection. An alternative view is to res-
erve nodal dissection for patients with high risk of nodal dis-
ease. However, the risk of nodal disease that warrants the
procedure is debated (3%, 5%, 10%, etc.). In endometrial
cancer, major complication rates associated with nodal
dissection are 2% to 6%, suggesting that this might be an
appropriate level of risk to balance against the risk of nodal
metastases. The GOG 33 study provides important data that
can be used to decide whether to perform nodal assessments
based on tumor grade and depth of invasion and frequency
of nodal disease [37]. For example, the risk of pelvic nodal
disease was 3% for all patients with grade 1 tumors, but
was 11% with deeply invasive (outer one-third myometrial
invasion) tumors. Patients with grade 3 tumors had a risk of
pelvic nodal metastases of 18% and 34% with deep invasion.
Patients with serous or clear cell histology also warrant nodal
dissection as 30% to 50% will have nodal disease [63]. It
seems that the depth of myometrial invasion is the most
important factor that determines the likelihood of nodal
involvement [37, 64, 65].
Selective lymph node dissection based on palpation
is inaccurate as only 10% of patients with metastases to
lymphnodeswillhavegrosslyenlargednodesandfrequently,
even in these cases, direct palpation through the overlying
peritoneum will fail to identify them [37].
Intraoperative assessment of the uterus has been used
to guide the surgeon as to when to perform a nodal dis-
section, with gross inspection of the uterus immediately fol-
lowing its removal to estimate the degree of myometrial
invasion. However, there is no typical gross appearance of an
endometrial carcinoma. Frozen section assessment has been
suggested as a tool to facilitate decisions on selective nodal
dissections. Several studies have demonstrated inaccuracies
with frozen sections in the interpretation of grade and depth
ofmyometrialinvasioncomparedtoﬁnalpathology[66,67].
In one prospective evaluation, frozen section determination
of depth of invasion correlated with ﬁnal pathology in 67%
of cases but resulted in upstaging in 28% of cases [67].
6.3. Routine Lymphadenectomy. The strongest argument for
routine staging is the avoidance of pelvic radiation therapy
following thorough nodal assessment and conﬁrmation of
node-negative disease and low risk status. In the absence of
nodal disease, recurrence risk is low and overall survival is
high, with no radiation or with the substitution of vaginal
vaultbrachytherapy.Thishasencouragedmanygynaecologic
oncologists to move towards performing routine surgical
staging including pelvic and para-aortic lymphadenectomy
for nearly all patients with endometrial cancer.
The rationale for routine uniform staging is the inaccu-
racy of preoperative or intraoperative assessments predicting
the risk for nodal disease, the potential for therapeutic bene-
ﬁtinnode-positiveand-negativepatients,andthelackofsig-
niﬁcant morbidity associated with the procedure, with major
complication rates of 2% to 6%. It could thus be argued
thatroutinenodaldissectionisthebestmethodtodetermine
whichfewpatientswillrequireadjuvanttherapy.Inaddition,
there is a signiﬁcant risk of lymph node spread even for pa-
tientswithseeminglylow-riskdisease.Datasuggestthatstage
IA grade 1 disease has a 1% risk of para-aortic and a 2% risk
of pelvic lymph node metastases, while stages IA grade 2 and
IB grade 1 have a 2% risk of para-aortic and a 4% risk of
pelvic lymph node metastases. Stage IB grade 2 disease has a
2% risk of para-aortic and a 6% risk of pelvic lymph node
metastases [68].
However, a randomized controlled trial in which women
with stage I endometrial cancer were assigned to have a
standard hysterectomy and ovary removal with or with-
out lymphadenectomy found that systematic use of pelvic
lymphadenectomy does not improve disease-free or overall
survival in women with early-stage endometrial cancer [69].
Withamedianfollowupoffouryears,therewasnodiﬀerence
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(12.9%) of the 264 patients in the lymphadenectomy arm
and 33 (13.2%) of the 250 patients in the control arm had
disease recurrence. The median time to disease recurrence
was 14 months in the lymphadenectomy arm and 13 months
in the control arm. Overall ﬁve-year survival estimates were
86% for the lymphadenectomy arm and 90 percent for the
nonlymphadenectomy. Surgical staging of the disease was
improved with the systematic use of lymphadenectomy. A
total of 13.3% of the women in the lymphadenectomy arm
were found to have disease spread to pelvic lymph nodes,
compared with 3.2% of the women in the control arm. The
investigators found that although lymphadenectomy was not
statistically signiﬁcantly associated with improved survival,
disease spread to the nodes was associated with poorer sur-
vival. Therefore, lymphadenectomy maintained its impor-
tance in determining a patient’s prognosis and in tailoring
adjuvant therapies [69].
7. Extentof Lymphadenectomy
The clinic-pathologic factor most strongly related to para-
aortic nodal metastasis is pelvic lymph node metastasis [70].
Among patients who underwent systematic pelvic and para-
aortic lymphadenectomy, 96.2% had negative para-aortic
nodes when the pelvic nodes were negative. However, when
the pelvic nodes were positive, 48% also had positive para-
aortic nodes [70, 71]; hence, systemic para-aortic lympha-
denectomy is advocated on all high-risk patients, or in pa-
tients with two or more positive pelvic lymph nodes [71, 72].
However, this is a major surgery to undertake in pa-
tients who are usually elderly and obese, with other comor-
bidities. An extensive para-aortic lymphadenectomy signiﬁ-
cantly increases operating time and blood loss and also
increases postoperative morbidity, particularly lower limb
lymphoedema (in about 20% of patients) [73]. Lymphoed-
ema is often complicated by recurrent episodes of cellulitis.
It could thus be argued that primary prevention of lympho-
edema by selective use of pelvic lymphadenectomy and avoi-
dance of systematic para-aortic lymphadenectomy is highly
desirable.
8. Therapeutic Role of Lymphadenectomy
The therapeutic role of lymphadenectomy is less well under-
stood, but its ability to modify adjuvant therapy is being
increasingly accepted. The ﬁrst suggestion of a therapeutic
value for pelvic lymphadenectomy was by Kilgore et al.
[74]. With a mean followup of 3 years, patients undergoing
multiple-site pelvic node sampling had a signiﬁcantly better
o v e r a l ls u r v i v a la sw e l la sab e t t e rs u r v i v a lf o rb o t hl o w -
risk and high-risk groups. An explanation for the increased
survival in low-risk groups may be the removal of unrecog-
nized micrometastasis, which goes undetected by standard
pathologic processing techniques.
Conversely, the current available evidence from the
ASTEC trial does not support the claim that lymphadenec-
tomy in endometrial cancer is therapeutic [57]. Unfortun-
ately, there are several reasons why the ASTEC trial could
have failed to show improved overall survival with routine
lymphadenectomy. The trial required only a pelvic lympha-
denectomy and utilized a second randomization for pelvic
radiation for disease characteristics, which, following a nega-
tive nodal dissection, is typically avoided. Likewise, vaginal
vault radiation was permitted as per institutional practice ir-
respective of the assignment to pelvic radiation or not, mak-
ing interpretations of any results likely diﬃcult. The number
of lymph nodes resected was insuﬃcient in many patients.
Equally, there was a high rate of inclusion of low-risk pa-
tients, and the low number of lymph nodes removed could
be the reason for the low rate of involved lymph nodes seen
in the lymphadenectomy group.
9.PredictingNodal Disease
In an attempt to minimize the impact of lymphadenectomy
and assist selective lymph node dissection, eﬀorts have been
paid towards predicting nodal disease using positron emis-
sion tomography (PET). It seems that 18F-FDG PET/CT is
an accurate method for the presurgical evaluation of pelvic
nodes metastases with high sensitivity, speciﬁcity, and posi-
tive predictive value (nearing 100%) [75, 76]. High negative
predictive value (93.1–97.2%) may be useful in selecting pa-
tientswhoonlymaybeneﬁtfromlymphadenectomyinorder
to minimize operative and surgical complications [77]. Con-
versely, other studies found that FDG-PET is only moder-
atelysensitiveinpredictinglymphnodemetastasispreopera-
tivelyinpatientswithendometrialcarcinomawithsensitivity
and speciﬁcity of FDG-PET which were 60% and 98%, res-
pectively [78, 79].
In an attempt to avoid complete lymphadenectomy, the
concept of sentinel node identiﬁcation has been investigated
in endometrial carcinoma [80–87]. Data are scant, and stud-
ies are still addressing feasibility and standardization of tech-
nique. Many problems arise with the use of sentinel lymph
node dissection. First, the lymphatic drainage of the uterus
is considerably more complicated than that of the vulva and
cervix. Second, there is no easily accessible or visible lesion in
endometrial cancer as there is in vulvar or cervical cancers,
making injection diﬃcult. Third, the variation of reported
locations of sentinel nodes ranges from the parametrium to
thepara-aortic regiononeithersideofthebody. Theseissues
regarding the primary tumor and the patterns of lymphatic
drainage make sentinel lymph node biopsy for endometrial
carcinoma less practical.
10. Adjuvant RadiationTherapy
Radiation therapy has been crucial in the management of
endometrial cancer, whether used as an adjuvant treatment
after surgery or as deﬁnitive treatment for patients who are
medically inoperable or with local recurrence.
The need for postoperative radiotherapy is usually deter-
mined by prognostic features obtained from the pathology
review. Several studies suggested that survival rate increases
if surgery is performed in conjunction with adjuvant pelvic
radiotherapy, external beam radiotherapy (EBRT), or6 Obstetrics and Gynecology International
brachytherapy(BT)[88,89].Radiationtherapydecreasesthe
risk of pelvic recurrence [90]. Postoperative radiotherapy in
women with stage II endometrial carcinoma patients led to
an improved 5-year disease-free survival [91]. Similar results
were observed in women with stage IIIC endometrial carci-
noma receiving adjuvant EBRT and EBRT/BT. When direct
extension of the primary tumor was present, the addition
of BT to EBRT was even more beneﬁcial [92]. Women with
stageIIendometrialcarcinomawhodidnotreceiveradiation
were 48% more likely to die from their tumours. The beneﬁt
of adjuvant radiation is most pronounced in women with
high-risk pathologic features [93].
However,itseemsthatadjuvantpelvicradiotherapyleads
t oa ni m p r o v e dl o c a lc o n t r o lb u tn oo v e r a l ls u r v i v a la d v a n -
tage, particularly in low risk endometrial cancer patients
[94].Actually,inlow-riskpatientsadjuvantEBRTisprobably
detrimental whilst for intermediate-risk patients although
theremaybeasmallbeneﬁtforsomepatients;thisisoﬀsetby
additional morbidity leading to an overall neutral eﬀect [95–
97]. Data from the ASTEC/EN.5 showed no evidence that
overall survival with external beam radiotherapy was better
than observation (hazard ratio 1.04; 95% CI 0.84–1.29). As
such,adjuvantexternalbeamradiotherapycannotberecom-
mended as part of routine treatment for women with inter-
mediate-risk or high-risk early-stage endometrial carcinoma
with the aim of improving survival [98]. In the PORTEC-1
trial,the5-yearriskofvaginalandpelvicrecurrenceforhigh/
intermediate risk patients was 19% without further treat-
ment, compared to 5% after EBRT.
Brachytherapyisperceivedtobeamoreconvenientmode
of treatment compared to external beam radiotherapy and
might be associated with less toxicity. PORTEC-2 compared
the eﬃcacy of vaginal BT and EBRT to determine which
treatment provides optimal local control with best quality of
life.Thedatasuggestedthatvaginalbrachytherapyiseﬀective
in preventing vaginal recurrence. Despite the slightly but
signiﬁcantly increased pelvic failure rate in the VBT arm,
rates of distant metastases, OS, and RFS were similar [99].
Vaginal brachytherapy provided a better quality of life than
external-beam radiotherapy for endometrial carcinoma and
should be the preferred treatment from a quality of life per-
spective [100].
11. AdjuvantChemotherapy
The value of adjuvant systemic chemotherapy in patients
with high-risk early stage endometrial cancer is still contro-
versial.
The GOG 34 trial, using single-agent doxorubicin, did
not show any beneﬁt women with clinical stage I or II
(occult) disease who had one or more risk factors for recur-
rence after surgical staging [101]. Comparing 5 cycles of cis-
platin, doxorubicin, and cyclophosphamide with external
pelvic radiation, there was no diﬀerence between therapies
in terms of progression-free or overall survival [102].
In patients with stages IC to IIIC endometrioid adeno-
carcinoma, there were no signiﬁcant diﬀerences in disease-
f r e eo ro v e r a l ls u r v i v a la tam e d i a nf o l l o w u po f5y e a r s ,
between those treated with whole-pelvic irradiation or those
who received three or more cycles of cyclophosphamide,
doxorubicin, and cisplatin [103].
PORTEC-3 study is a phase III randomized trial compar-
ing chemoradiation and adjuvant chemotherapy (4 cycles of
carboplatin and paclitaxel) versus pelvic radiation alone in
highriskandadvancedstagedisease.Thestudyshoulddeter-
mine whether radiotherapy or chemotherapy improves over-
allsurvivalandfailure-freesurvival,comparetheratesofsev-
ere(grades3and4)treatment-relatedtoxicity,pelvicanddis-
tant recurrence, and evaluate quality of life of patients with
high-risk and advanced stage endometrial carcinoma.
Two additional GOG studies are currently open for re-
cruitment and are examining the role of adjuvant chemo-
therapy in the treatment of endometrial carcinoma. The
GOG 249 is a randomised phase III trial studying pelvic rad-
iationtherapytoseehowwellitworkscomparedwithvaginal
implant radiation therapy, paclitaxel, and carboplatin in
treatingpatientswithhigh-riskstageIorstageIIendometrial
cancer. The GOG 258 is a randomised phase III trial com-
paring the recurrence-free survival of patients with stage I-
IVA endometrial carcinoma treated with adjuvant chemora-
diotherapy comprising cisplatin and tumor volume-directed
radiotherapy followed by carboplatin and paclitaxel versus
carboplatin and paclitaxel alone. The results of these trials
are awaited by 2014.
12. Endometrial CarcinomasinYoung Women
Less than 5% of endometrial cancers occur in women aged
40 years or younger, and the majority are well-diﬀerentiated
tumours (90% of lesions) and are limited to the endomet-
rium [104]. A more variable histologic pattern may occur in
association with Lynch syndrome (HNPCC) [105]. Fertility
preservationcouldbeanissueinthesepatientsandprogesta-
tionaltherapymaybeused.Endometrialcarcinomahasbeen
reported to progress in 80% of cases with various proges-
tational agents (e.g., megestrol acetate 160–320mg/day or
medroxyprogesterone acetate 200–500mg/day) [106–110];
however, successful pregnancies have been reported in only
40% of these women. A decision for uterine preserving treat-
ment should not be taken lightly. It is crucial to exclude the
presence of signiﬁcant myometrial invasion by MRI and to
ascertain a grade 1 histology and progesterone receptor posi-
tive status. Ovarian pathology has to be excluded in particu-
lar in association with Lynch syndrome [111] and to rule out
synchronous primary or metastatic disease [112]. The endo-
metrial response needs to be assessed after 3 months of pro-
gestational treatment. Unfortunately, about 40% of patients
who initially respond will recur [106–110], hence the need
for prolonged surveillance and the recommendation for hys-
terectomy once childbearing is completed.
13. Summary
Endometrial cancer is the most common gynecologic malig-
nancy, and an understanding of presentation, surgical man-
agement, and treatment options is required for gynecologic
oncologists. Surgical therapy is a mainstay of endometrialObstetrics and Gynecology International 7
cancer treatment with lymphadenectomy and laparoscopy
being increasingly integrated. A thorough knowledge of the
relationships between uterine factors and extrauterine dis-
ease spread is essential. At present, surgical staging better
deﬁnes extent of disease and largely deﬁnes risk of recur-
rence. Pelvic radiation is associated with better local control.
In the published trials, there was no improvement in survival
for selected patients with stage I-II endometrial cancer, as
these trials did not include patients at high risk of recurrence
and death. Chemotherapy is increasingly integrated into up-
front management of advanced-stage endometrial cancer
andmayhavearoleinearly-stagedisease.Combinationther-
apy with radiation and chemotherapy is under evaluation.
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